Marsh B
1 , Sampson JM 1 North Florida /South Georgia VA Medical Center, Gainesville, FL, USA OBJECTIVES: To study the prevalence of erectile disorder in males with chronic pain on opioids. Chronic pain can lead to reduced quality of life and strain on relationships. Opioids themselves can lead to significant side effects, including a reduction in serum testosterone and interference in the hypothalamicpituitary-axis. METHODS: Male patients in an opioid clinic with chronic pain on opioids were screened for erectile disorder. RESULTS: Ninety five patients were screened and 27 patients 29%) were positive for the disorder. Only ten (37%) had received treatment. CONCLUSIONS: Erectile disorder is an under diagnosed and treated disorder in chronic pain patients on opioids. Male patients with chronic pain should be routinely screened for erectile disorders.
PAIN-Cost Studies

PPN2 IMPACT OF BACK PAIN ON ABSENTEEISM, PRODUCTIVITY LOSS, AND DIRECT HEALTH CARE COSTS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Parthan A, Shepherd MD, Lawson KA, Barner JC, Brown C, Bohman T University of Texas at Austin, Austin, TX, USA OBJECTIVE: The objective of this study was to assess the impact of back pain on absenteeism, productivity loss, and direct health care costs using the Medical Expenditure Panel Survey (MEPS). METHODS: Individuals between the ages of 18 and 65 years who participated in the MEPS during 2000 were included in the study. Back pain patients were identified using ICD-9 codes. The predictors of absenteeism in individuals who experienced back pain were identified using Zero-inflated negative binomial regression (ZINB). Absenteeism days due to back pain were estimated based on the ZINB regression model. Productivity loss was estimated using the human capital approach. RESULTS: In 2000, the one-year period prevalence of back pain in individuals between 18 and 65 years of age was 11.1%. About 16.3% of the individuals who were employed and who reported back pain experienced back pain due to work-related injuries. Ethnicity and union contract were identified as significant predictors of likelihood of absenteeism in individuals who experienced back pain. The significant predictors of absenteeism rate were perceived overall health status due to back pain, and ethnicity. The mean number of absenteeism days due to back pain was estimated to be six days and a total of nine million absenteeism days were due to back pain. The total productivity loss due to back pain-related absenteeism was estimated to be $3.6 billion and the total direct health care costs was estimated to be $14 billion. The average productivity loss due to back pain was estimated to be $305 per person and the annual per-capita direct health care cost due to back pain was $730. CONCLUSIONS: Back pain is one of the most common and challenging problems in primary care. The economic burden due to back pain is of concern to employers, insurance agencies, policy decision makers and treatment decision makers.
PAIN-Health Care Use & Policy
PPN3 THE PRICING AND DISTRIBUTION OF REPACKAGED DRUGS: COST EFFECTS IN THE CALIFORNIA WORKERS
University of California, San Francisco and Amgen, Inc, San Francisco, CA, USA, 2 University of California, San Francisco, San Francisco, CA, USA OBJECTIVE: The California Workers' Compensation (WC) drug pricing system effective in 2004 tied payments to the MediCal system, but 60% of National Drug Codes (NDC) in the WC System lacked an equivalent Medi-Cal NDC; and many were repackaged pharmaceuticals. A model of pharmaceutical distribution and claims processing of repackaged pharmaceuticals was defined. We assessed the cost and utilization of repackaged pharmaceuticals to determine potential lost savings to the California WC system. METHODS: We used 2002 data from the California Workers' Compensation Institute and Medi-Cal pharmacy expenditures. We described the extent of lost savings due to repackaged pharmaceuticals, compared the characteristics of repackaged pharmaceuticals in the WC using ANOVA, and identified predictors of repackaged pharmaceuticals using GLM regression. We also suggest alternative pricing systems for MediCal non-equivalent repackaged NDCs. RESULTS: Repackaged pharmaceuticals represented 55% of the Medi-Cal nonequivalent NDCs used, but only 21% of total WC costs ($8,494,297) were attributed to repackaged pharmaceuticals. Approximately 88% of repackaged pharmaceutical costs were for generic medications. Companies most commonly associated with repackaged pharmaceutical costs were Southwood Pharmaceuticals (33.1%) and Pharma Pac (31.7%). Overall, com-pared to the $125 million in savings attributed to the Medi-Cal equivalent NDCs, an additional $8 million could be gained if repackaged pharmaceuticals were priced with a relevant MediCal rate such as an average Estimated Acquisition Cost, an overall savings of 35.8%. On a per prescription basis, the practice of repackaging costs an additional $20 when compared to a Medi-Cal pharmacy dispensed reimbursement rate. CONCLU-SION: This study informs new legislation being proposed to stop the generous pricing of repackaged pharmaceuticals due to nonequivalent NDCs. For the first time we describe the practice of repackaging pharmaceuticals and identify cost savings expected with alternative pricing systems, but also identify the value of repackaging pharmaceuticals for WC patients.
PPN4 PATIENT SEGMENTATION AND DRIVERS OF ACCESS TO PATIENT CONTROLLED ANALGESIA
Nuyts G, Jones MP Johnson and Johnson, Raritan, NJ, USA OBJECTIVES: Patient controlled analgesia (PCA) with pump delivery is the mainstay of modern postoperative pain management, with often better pain control compared to competing methods. We performed a data mining study to identify the clinical and hospital infrastructure correlates of PCA use. METHODS: Patients older than 18 years having major operative procedures expected to require strong opioid based postoperative pain control were selected from the Premier Perspective database. Obstetric patients were excluded. Two random samples were selected: a training sample of N = 21,782 and a validation sample of N = 21,538. Factor analysis mapped the 75 observed explanatory variables, not related to post-operative pain method onto 17 independent factors. Patient segmentation was performed based on cluster analysis. RESULTS: Thirteen distinct clusters were identified each with distinguishing demographic, clinical, payor and hospital setting features. Percent of PCA use in each of the segments ranged from 3% to 38%. Six segments, accounting for 3.5%, 1.8%, 8.4%, 4.1%, 6.1% and 9.2% of the total population had PCA usage below 10%. Only three segments had PCA usage more than 20% with 4.7%, 14.5% and 7.8% of the population. Qualitative evaluation indicated that the primary factor determining whether a segment had low or high PCA use was the circumstance of admission: for urgent admissions PCA was lowest, while the highest PCA use was observed in those segments characterized by elective admissions. CONCLUSION: Use of PCA differs between segments in a heterogeneous cohort of post-operative pain patients. That the driver of this difference was admission source may suggest that time required to prepare PCA is an important factor in its actual use and that thus easier PCA methods may increase patient's use of PCA.
PAIN-Patient Reported Outcomes
PPN5 ADVANCES IN PAIN MEASUREMENT: ITEM RESPONSE THEORY (IRT) BASED METHODS AND THE PAIN IMPACT QUESTIONNAIRE (PIQ-6)
Becker J, Saris-Baglama RN, Bjorner JB, Kosinski M, Ware JE QualityMetric Incorporated, Lincoln, RI, USA OBJECTIVES: To use IRT-based methods to develop a six-item questionnaire (PIQ-6) measuring pain severity and pain impact. IRT was used to: 1) identify the most informative items from a bank of 65 items, 2) evaluate construct validity, 3) norm the PIQ-6 to the US general population; 4) cross-calibrate it to the SF36v2 BP scale; 5) develop a simple scoring approach based on response category weights matching the IRT score; and 6) build a computerized version to facilitate monitoring and management of pain. METHODS: Items analyses and selection were based on data from two web-based general population samples (n = 782, n = 829) and a chronic pain patients sample (n = 306). Norming was achieved by recalibrating the IRT-based item parameter using 1998 US representative norm data of the SF36v2 (n = 7069). Cross-calibration of the PIQ-6 and SF-36v2 was performed by estimating the expected SF-36v2 BP scale score using IRT-based item parameter. The PIQ-6 computerized version was programmed with Microsoft Visual Basic. RESULTS: Six items were identified that fitted an unidimensional IRT model, showed high measurement precision and did not show differential item functioning. Construct validity was supported by high correlations with other pain measures and strong discrimination of pain patients and the general population. The PIQ-6 is normed so that a score of 50 represents the US general population norm (sd = 10). A cross-calibration table of the PIQ-6/SF-36v2 was created to facilitate communication between researchers using those different instruments. The simple hand scoring approach had satisfactory agreement with the IRT scores. The PIQ-6 was programmed as computerized stand-alone/PDA/online versions allowing for an easy administration, scoring and immediate feedback reporting including interpretation guidelines. CONCLU-SIONS: Pain measurement can be improved by using IRT and computerized methods. Noteworthy advantages of the PIQ-6 are the enhancement of measurement precision and coverage as well as the facilitation of monitoring and managing pain. = 45,754 ) and up to a maximum of 6 years. Compliance was calculated as the "simple" medical possession ratio (MPR)-days supply/ 365 days-and as "adjusted" MPR, systematically accounting for gaps and surplus days supply. Persistence was calculated as "continuous" statin persistence (no gap in supply greater than 30 days) and as "any" statin supply per one year periods. Gaps were calculated for number of gaps of one day or more without days supply and average gap length in 365 days. RESULTS: "Simple" MPR in the first year of use was 62% (S.D. = 0.36). For the same period "adjusted" MPR was 59% (S.D. 0.33) and lower for 50% of the sample. The average difference was 0.04 (14.6 days). Approximately 34% of the sample was continuously persistent thru year 1, falling to 21% in year 2; however, 73 percent had at least one prescription in year 2. Compliance, persistence and gaps varied year by year over patient's total coverage periods. CONCLUSIONS: Failure to account for gaps and cumulative surpluses in prescription refills can distort compliance estimates. "Any" persistence statistics indicate that a higher proportion of statin users remain intermittent rather than discontinued over long periods of time. Statistics on number and length of gaps are necessary to provide a full
PATIENT-REPORTED OUTCOMES
